Botulinum toxin: an endoscopic approach for treating fecal incontinence

Background and study aims: Fecal incontinence is a common, distressing condition with limited therapeutic options. Botulinum toxin A (BTX-A) injections have been proposed as a treatment for patients with fecal incontinence. This study aimed to determine the short-term clinical outcomes of BTX-A injections in patients with fecal incontinence of varying etiology.

Patients and methods: Twenty-six patients with fecal incontinence were enrolled, 17 with their native rectum and 9 with a neo-reservoir following a proctectomy for rectal cancer. BTX-A was endoscopically injected into the rectum/reservoir. Scores for severity (CCS) and quality of life (FIQL) were recorded at baseline and at the 3-month follow-up visit.

Results: The CCS was significantly lower after 3 months (median 15, range 4 – 20 vs. 8, range 1 – 19; P = 0.001). The quality of life improved in three of the four FIQL domains. The improvement was maintained in 11 of 12 patients who received more than one injection because of recurrent symptoms. There was no significant predictive factor for the success of BTX-A injections.

Conclusion: This preliminary study demonstrated that rectal/reservoir injections are an effective short-term treatment for fecal incontinence.

• References

• 1 Damon H, Guye O, Seigneurin A et al. Prevalence of anal incontinence in adults and impact on quality-of-life. Gastroenterol Clin Biol 2006; 30: 37-43
• 2 Whitehead WE, Rao SS, Lowry A et al. Treatment of fecal incontinence: state of the science summary for the National Institute of Diabetes and Digestive and Kidney Diseases workshop. Am J Gastroenterol 2015; 110: 138-146
• 3 Denys P, Le Normand L, Ghout I et al. Efficacy and safety of low doses of botulinum toxin type A for the treatment of refractory idiopathic overactive bladder: a multicentre, double-blind, randomised placebo-controlled doses ranging study. Eur Urol 2012; 61: 520-529
• 4 Herbst F, Kamm MA, Morris GP et al. Gastrointestinal transit and prolonged ambulatory colonic motility in health and faecal incontinence. Gut 1997; 41: 381-389
• 5 Guillemot F, Leroy J, Boniface M et al. Functional assessment of coloanal anastomosis with reservoir and excision of the anal transition zone. Dis Colon Rectum 1991; 34: 967-972
• 6 Bridoux V, Gourcerol G, Kianifard B et al. Botulinum A toxin as a treatment for overactive rectum with associated faecal incontinence. Colorectal Dis 2012; 14: 342-348
• 7 Gallas S, Leroi AM, Bridoux V et al. Constipation in 44 patients implanted with an artificial bowel sphincter. Int J Colorect Dis 2009; 24: 969-974
• 8 Gourcerol G, Gallas S, Michot F et al. Sacral nerve stimulation in fecal incontinence: are there factors associated with success?. Dis Colon Rectum 2007; 50: 3-12
• 9 Savoye-Collet C, Savoye G, Koning E et al. Endosonography in the evaluation of anal function after primary repair of a third-degree obstetric tear. Scand J Gastroenterol 2003; 38: 1149-1153
• 10 Jorge JM, Wexner SD. Etiology and management of fecal incontinence. Dis Colon Rectum 1993; 36: 77-97
• 11 Rullier E, Zerbib F, Marrel A et al. Validation of the French version of the Fecal Incontinence Quality-of-Life (FIQL) scale. Gastroenterol Clin Biol 2004; 28: 562-568
• 12 Gallas G, Michot F, Faucheron JL et al. Predictive factors for successful sacral nerve stimulation in the treatment of faecal incontinence: results of trial stimulation in 200 patients. Colorectal Dis 2011; 13: 689-696
• 13 Grosse J, Kramer G, Stohrer M. Success of repeat detrusor injections of botulinum A toxin in patients with severe neurogenic detrusor overactivity and incontinence. Eur Urol 2005; 47: 653-659